All In Biotech

Drug Trial Radar · NCT04477291

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

45

Actual

Start

Oct 6, 2020

Primary completion

Apr 15, 2024

Study completion Apr 15, 2024

Sponsor

Lead sponsor
Aptose Biosciences Inc.Industry
Sponsor type
Industry
First posted
Jul 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes

Interventions

  • CG-806Drug

    CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events of CG-806Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Establish a CG-806 dose that maintains a biologically active plasma concentrationTime frame: At the end of Cycle 1 (each cycle is 28 days)
  3. Establish a recommended dose for future development of CG-806Time frame: At the end of Cycle 1 (each cycle is 28 days)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • University of Southern California

    Los Angeles, California

  • University of Miami

    Miami, Florida

  • Northwestern University

    Chicago, Illinois

  • Ochsner Healthcare

    New Orleans, Louisiana

  • Atlantic Hematological Oncology Center

    Morristown, New Jersey

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University Hospital of Cleveland

    Cleveland, Ohio

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.